Developer docs
API playgroundTry for free, no card

Search company profiles

GrapheneDx

Full company profile

uuid000953j

Namestring
GrapheneDx
Legal namestring
GrapheneDx, Inc.
Websiteurl
graphenedx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

GrapheneDx, Inc. is a Boston-based diagnostics company developing handheld at-home testing devices built on a graphene field effect transistor (GFET) biosensor platform. The core technology uses a one-atom-thick layer of carbon atoms arranged in a hexagonal lattice to detect disease biomarkers with high electron mobility, targeting lab-quality accuracy in under five minutes across a portfolio of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. The product system comprises a central handheld reader plus a portfolio of sample collection accessories designed for blood, urine, saliva, and stool, with multiplexing capability for concurrent analyte detection and minimal sample preparation. First commercial tests are focused on chlamydia and gonorrhea using non-invasive urine samples.

GrapheneDx operates as a Sapphiros Group Company, majority-owned by Sapphiros, a diagnostics platform formed in July 2021 by KKR's Health Care Strategic Growth strategy and former Smith & Nephew/Alere CEO Namal Nawana, with additional backing from Neoenta. Co-founded in 2020 by Mohammed Fotouhi, the company merged with Rite Taste, LLC that same year and relocated to Boston's Seaport district in September 2021 to support growth. Mike Musgnug was appointed CEO in September 2022 while also serving as EVP Strategy for Sapphiros.

The business model centers on hardware sales of diagnostic devices and associated test kits across two primary go-to-market motions: direct-to-consumer for at-home testing and sales-led distribution into point-of-care healthcare settings, leveraging Sapphiros's commercial organization and channel partner relationships. Commercial manufacturing is enabled through a June 2023 strategic partnership with General Graphene Corp, which supplies sheet-based CVD graphene at 100,000 square meters of annual capacity, combined with Sapphiros's extreme volume manufacturing (EVM) facility capable of 5 billion tests per year. Revenue has not commenced; the company is pre-commercial.

Short descriptiontext

GrapheneDx develops handheld at-home diagnostic devices using graphene field effect transistor (GFET) biosensor technology to deliver lab-quality results in under five minutes. The Boston-based company, majority-owned by KKR-backed Sapphiros, serves consumers and point-of-care healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
graphene biosensor technology, at-home diagnostic devices, point-of-care diagnostics, molecular diagnostics, consumer health testing
Industry2 codes
PRIMARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Laboratory Analytical Instruments3826
Product category
At-Home Diagnostic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Tests and Devices
TypeHardware Sales
Description

Sale of handheld diagnostic devices and associated test kits for at-home and point-of-care use. Products include tests for sexually transmitted infections, respiratory disease, cardiac disease, concussion, and other conditions using various sample types.

graphenedx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GrapheneDx designs and sells handheld at-home diagnostic devices powered by a proprietary graphene field effect transistor (GFET) biosensor platform that delivers lab-quality diagnostic results in under five minutes. The platform supports multiple sample types (blood, urine, saliva, stool) via dedicated collection accessories and is being developed to detect a range of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. First commercial tests target STIs (chlamydia and gonorrhea) using non-invasive urine samples.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results in less than 5 minutes
+2 more records
Product overview1 text field

GrapheneDx offers a unified at-home diagnostic testing platform centered around a handheld graphene field effect transistor (GFET) biosensor device. The platform supports multiple sample collection accessories (blood, urine, saliva, and stool collection devices) that work with the core handheld device to enable rapid, lab-quality diagnostic testing for various disease states including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. Results are delivered in under five minutes with minimal or no sample preparation required.

Product and service5 records
1GrapheneDx Handheld Diagnostic Device
CategoryCore Diagnostic Device
Description

A handheld at-home testing device utilizing graphene field effect transistor (GFET) biosensor technology that provides lab-quality diagnostic results in under five minutes for various disease states and sample types. Designed for use by individual consumers at home and by medical professionals at point-of-care settings.

2Blood Collection Device
CategorySample Collection Accessory
Description

Sample collection device designed for blood-based diagnostic testing with the GrapheneDx handheld diagnostic platform.

3Urine Collection Device
CategorySample Collection Accessory
Description

Sample collection device designed for urine-based diagnostic testing with the GrapheneDx platform, featuring a front tab for collection and a back tab designed as a reservoir for user guidance.

4Saliva Collection Device
CategorySample Collection Accessory
Description

Sample collection device designed for saliva-based diagnostic testing with the GrapheneDx platform.

5Stool Collection Device
CategorySample Collection Accessory
Description

Sample collection device designed for fecal/stool sample diagnostic testing with the GrapheneDx platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1General Graphene Corporation
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-06
Description

Strategic partnership to industrialize graphene-based biosensors. General Graphene Corp serves as GrapheneDx's preferred supplier of sheet-based chemical vapor deposition (CVD) graphene delivered in roll-to-roll format for use in Sapphiros's extreme volume manufacturing facility. General Graphene has existing annual capacity of 100,000 square meters of sheet graphene.

graphenedx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-06
Description

Sapphiros is a platform company dedicated to building the next generation of consumer diagnostic technologies, backed by KKR and Neoenta. Sapphiros contributes expertise in extreme volume manufacturing (EVM) with capacity of 5 billion tests per year, including printed electronics and printed battery technology. GrapheneDx is a Sapphiros Group Company.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

Mike Musgnug joined Sapphiros as EVP Strategy and CEO of GrapheneDx, leading strategy development and business development for Sapphiros in addition to leading the GrapheneDx organization. Sapphiros provides operational support and resources to GrapheneDx.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-21
Description

British molecular diagnostics company acquired by Sapphiros alongside GrapheneDx. Applies novel isothermal amplification methods to disposable and point-of-care diagnostic technologies. Part of the same cohort of innovative diagnostics companies under Sapphiros platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Cue Health
TypeDirect peer
Description

Cue Health markets a connected at-home molecular diagnostic platform (respiratory, sexual health) directly to consumers — the same direct-to-consumer, handheld, rapid-result positioning GrapheneDx is targeting with its GFET device.

TypeDirect peer
Description

Visby Medical develops handheld PCR-based diagnostic devices for at-home and point-of-care STI and infectious disease testing — closely comparable in form factor, target use cases, and consumer/POC GTM.

3Lucira Health
TypeDirect peer
Description

Lucira (acquired by Pfizer) pioneered a single-use at-home molecular COVID test and was pivoting into broader respiratory/STI testing — a direct adjacency to GrapheneDx's at-home multiplex device strategy.

TypeBroad incumbent
Description

Cepheid is the established leader in molecular point-of-care diagnostics (GeneXpert); CEO Musgnug previously held commercial roles there, and the company anchors the POC molecular category GrapheneDx is targeting.

5Abbott Diagnostics
TypeBroad incumbent
Description

Abbott owns BinaxNOW, the Alere rapid-diagnostics franchise (acquired for $8B with Nawana at the helm), and the ID NOW platform — a broad incumbent in both at-home lateral-flow and POC molecular diagnostics.

TypeBroad incumbent
Description

BD is a global diagnostics and life sciences incumbent with a deep portfolio in molecular, rapid antigen, and POC testing, providing scale distribution and a relevant comparable for handheld diagnostic commercialization.

TypeBroad incumbent
Description

QuidelOrtho (formed via Quidel-Ortho merger) is a leading rapid-diagnostics player (Sofia, QuickVue) with strong at-home and POC presence in respiratory and infectious disease — directly comparable to GrapheneDx's initial target indications.

TypeEmerging player
Description

Mammoth is developing CRISPR-based molecular diagnostic platforms for at-home and POC use — an emerging peer competing on novel detection chemistry, broadly comparable in ambition though different in core technology.

TypeEmerging player
Description

Sherlock is commercializing CRISPR-based and synthetic biology molecular diagnostics (including at-home applications) — an emerging competitor in next-generation molecular detection adjacent to GrapheneDx's GFET platform.

TypeEmerging player
Description

T2 Biosystems develops rapid molecular diagnostic panels (sepsis, Candida) using a non-PCR detection technology for hospital use — an adjacent emerging player showing how novel detection chemistries can reach clinical scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GrapheneDx

At-Home Diagnostic Devicesgraphenedx.com

GrapheneDx develops handheld at-home diagnostic devices using graphene field effect transistor (GFET) biosensor technology to deliver lab-quality results in under five minutes. The Boston-based company, majority-owned by KKR-backed Sapphiros, serves consumers and point-of-care healthcare providers.

What GrapheneDx does

GrapheneDx, Inc. is a Boston-based diagnostics company developing handheld at-home testing devices built on a graphene field effect transistor (GFET) biosensor platform. The core technology uses a one-atom-thick layer of carbon atoms arranged in a hexagonal lattice to detect disease biomarkers with high electron mobility, targeting lab-quality accuracy in under five minutes across a portfolio of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. The product system comprises a central handheld reader plus a portfolio of sample collection accessories designed for blood, urine, saliva, and stool, with multiplexing capability for concurrent analyte detection and minimal sample preparation. First commercial tests are focused on chlamydia and gonorrhea using non-invasive urine samples.

GrapheneDx operates as a Sapphiros Group Company, majority-owned by Sapphiros, a diagnostics platform formed in July 2021 by KKR's Health Care Strategic Growth strategy and former Smith & Nephew/Alere CEO Namal Nawana, with additional backing from Neoenta. Co-founded in 2020 by Mohammed Fotouhi, the company merged with Rite Taste, LLC that same year and relocated to Boston's Seaport district in September 2021 to support growth. Mike Musgnug was appointed CEO in September 2022 while also serving as EVP Strategy for Sapphiros.

The business model centers on hardware sales of diagnostic devices and associated test kits across two primary go-to-market motions: direct-to-consumer for at-home testing and sales-led distribution into point-of-care healthcare settings, leveraging Sapphiros's commercial organization and channel partner relationships. Commercial manufacturing is enabled through a June 2023 strategic partnership with General Graphene Corp, which supplies sheet-based CVD graphene at 100,000 square meters of annual capacity, combined with Sapphiros's extreme volume manufacturing (EVM) facility capable of 5 billion tests per year. Revenue has not commenced; the company is pre-commercial.

GrapheneDx firmographics

Firmographics
Name
GrapheneDx
Legal name
GrapheneDx, Inc.
Website
https://graphenedx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
GrapheneDx develops handheld at-home diagnostic devices using graphene field effect transistor (GFET) biosensor technology to deliver lab-quality results in under five minutes. The Boston-based company, majority-owned by KKR-backed Sapphiros, serves consumers and point-of-care healthcare providers.
Ownership category
akta.pro rank

GrapheneDx industry classification

Industry
Product category
At-Home Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Graphene biosensor technology
  • At-home diagnostic devices
  • Point-of-care diagnostics
  • Molecular diagnostics
  • Consumer health testing

Where GrapheneDx is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GrapheneDx business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Tests and Devices: Sale of handheld diagnostic devices and associated test kits for at-home and point-of-care use. Products include tests for sexually transmitted infections, respiratory disease, cardiac disease, concussion, and other conditions using various sample types.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

GrapheneDx product offering

Product offering

Core offering

GrapheneDx designs and sells handheld at-home diagnostic devices powered by a proprietary graphene field effect transistor (GFET) biosensor platform that delivers lab-quality diagnostic results in under five minutes. The platform supports multiple sample types (blood, urine, saliva, stool) via dedicated collection accessories and is being developed to detect a range of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. First commercial tests target STIs (chlamydia and gonorrhea) using non-invasive urine samples.

Product overview

GrapheneDx offers a unified at-home diagnostic testing platform centered around a handheld graphene field effect transistor (GFET) biosensor device. The platform supports multiple sample collection accessories (blood, urine, saliva, and stool collection devices) that work with the core handheld device to enable rapid, lab-quality diagnostic testing for various disease states including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. Results are delivered in under five minutes with minimal or no sample preparation required.

Differentiator

Problem solved

Functional benefit

Products and services

  • GrapheneDx Handheld Diagnostic Device A handheld at-home testing device utilizing graphene field effect transistor (GFET) biosensor technology that provides lab-quality diagnostic results in under five minutes for various disease states and sample types. Designed for use by individual consumers at home and by medical professionals at point-of-care settings.
  • Blood Collection Device Sample collection device designed for blood-based diagnostic testing with the GrapheneDx handheld diagnostic platform.
  • Urine Collection Device Sample collection device designed for urine-based diagnostic testing with the GrapheneDx platform, featuring a front tab for collection and a back tab designed as a reservoir for user guidance.
  • Saliva Collection Device Sample collection device designed for saliva-based diagnostic testing with the GrapheneDx platform.
  • Stool Collection Device Sample collection device designed for fecal/stool sample diagnostic testing with the GrapheneDx platform.

Quantifiable outcome

  • Results in less than 5 minutes
  • +2 more outcomes

Companies that use GrapheneDx

Customer profile

Segments3 records

Ideal customer profiles2 records

GrapheneDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

GrapheneDx partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • General Graphene CorporationcoreTechnology or Integration · 6 June 2023Strategic partnership to industrialize graphene-based biosensors. General Graphene Corp serves as GrapheneDx's preferred supplier of sheet-based chemical vapor deposition (CVD) graphene delivered in roll-to-roll format for use in Sapphiros's extreme volume manufacturing facility. General Graphene has existing annual capacity of 100,000 square meters of sheet graphene.
  • SapphiroscoreStrategic or Co-development Partner · 6 June 2023Sapphiros is a platform company dedicated to building the next generation of consumer diagnostic technologies, backed by KKR and Neoenta. Sapphiros contributes expertise in extreme volume manufacturing (EVM) with capacity of 5 billion tests per year, including printed electronics and printed battery technology. GrapheneDx is a Sapphiros Group Company.
  • Sapphiros (Management)coreStrategic or Co-development Partner · 6 September 2022Mike Musgnug joined Sapphiros as EVP Strategy and CEO of GrapheneDx, leading strategy development and business development for Sapphiros in addition to leading the GrapheneDx organization. Sapphiros provides operational support and resources to GrapheneDx.
  • BiocrucibleminorStrategic or Co-development Partner · 21 July 2021British molecular diagnostics company acquired by Sapphiros alongside GrapheneDx. Applies novel isothermal amplification methods to disposable and point-of-care diagnostic technologies. Part of the same cohort of innovative diagnostics companies under Sapphiros platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

GrapheneDx competitors and assessment

Company assessment

Direct peers

  • Cue Health: Cue Health markets a connected at-home molecular diagnostic platform (respiratory, sexual health) directly to consumers — the same direct-to-consumer, handheld, rapid-result positioning GrapheneDx is targeting with its GFET device.
  • Visby Medical: Visby Medical develops handheld PCR-based diagnostic devices for at-home and point-of-care STI and infectious disease testing — closely comparable in form factor, target use cases, and consumer/POC GTM.
  • Lucira Health: Lucira (acquired by Pfizer) pioneered a single-use at-home molecular COVID test and was pivoting into broader respiratory/STI testing — a direct adjacency to GrapheneDx's at-home multiplex device strategy.

Broad incumbents

  • Cepheid (Danaher): Cepheid is the established leader in molecular point-of-care diagnostics (GeneXpert); CEO Musgnug previously held commercial roles there, and the company anchors the POC molecular category GrapheneDx is targeting.
  • Abbott Diagnostics: Abbott owns BinaxNOW, the Alere rapid-diagnostics franchise (acquired for $8B with Nawana at the helm), and the ID NOW platform — a broad incumbent in both at-home lateral-flow and POC molecular diagnostics.
  • Becton Dickinson (BD): BD is a global diagnostics and life sciences incumbent with a deep portfolio in molecular, rapid antigen, and POC testing, providing scale distribution and a relevant comparable for handheld diagnostic commercialization.
  • QuidelOrtho: QuidelOrtho (formed via Quidel-Ortho merger) is a leading rapid-diagnostics player (Sofia, QuickVue) with strong at-home and POC presence in respiratory and infectious disease — directly comparable to GrapheneDx's initial target indications.

Emerging players

  • Mammoth Biosciences: Mammoth is developing CRISPR-based molecular diagnostic platforms for at-home and POC use — an emerging peer competing on novel detection chemistry, broadly comparable in ambition though different in core technology.
  • Sherlock Biosciences: Sherlock is commercializing CRISPR-based and synthetic biology molecular diagnostics (including at-home applications) — an emerging competitor in next-generation molecular detection adjacent to GrapheneDx's GFET platform.
  • T2 Biosystems: T2 Biosystems develops rapid molecular diagnostic panels (sepsis, Candida) using a non-PCR detection technology for hospital use — an adjacent emerging player showing how novel detection chemistries can reach clinical scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

GrapheneDx social profiles

Digital presence

GrapheneDx compliance and trust

Trust signal

Compliance2 records

GrapheneDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GrapheneDx leadership team

Management profile

Number of profiles

Profiles8 records

GrapheneDx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GrapheneDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GrapheneDx

What does GrapheneDx do?

GrapheneDx designs and sells handheld at-home diagnostic devices powered by a proprietary graphene field effect transistor (GFET) biosensor platform that delivers lab-quality diagnostic results in under five minutes. The platform supports multiple sample types (blood, urine, saliva, stool) via dedicated collection accessories and is being developed to detect a range of conditions including sexually transmitted infections, respiratory disease, cardiac disease, and concussion. First commercial tests target STIs (chlamydia and gonorrhea) using non-invasive urine samples.

Is GrapheneDx a public or private company?

GrapheneDx is a private company. It is classified as private equity controlled and is currently operating.

When was GrapheneDx founded?

GrapheneDx was founded in 2020. It employs 1 to 10 people.

Where is GrapheneDx based?

GrapheneDx is headquartered in Boston, United States, in the North America region.

How does GrapheneDx make money?

One revenue line is on record: diagnostic Tests and Devices.

Who are GrapheneDx's main competitors?

Direct peers on record are Cue Health, Visby Medical and Lucira Health. Broad incumbents are Cepheid (Danaher), Abbott Diagnostics, Becton Dickinson (BD) and QuidelOrtho. Emerging players are Mammoth Biosciences, Sherlock Biosciences and T2 Biosystems.

Does GrapheneDx have an API?

No public API is recorded for GrapheneDx.

What industry is GrapheneDx in?

GrapheneDx's product category is At-Home Diagnostic Devices. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals